Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Etoricoxib (MK-663) 是一种合成的非甾体抗炎药 (NSAID),具有解热、镇痛和潜在的抗肿瘤特性。它是可口服的选择性 COX-2抑制剂,对人全血 COX-2 和 COX-1 的 IC50值分别为 1.1 和 116 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 197 | 现货 | ||
10 mg | ¥ 328 | 现货 | ||
25 mg | ¥ 529 | 现货 | ||
50 mg | ¥ 768 | 现货 | ||
100 mg | ¥ 1,320 | 现货 | ||
200 mg | ¥ 1,960 | 现货 | ||
500 mg | ¥ 3,330 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 226 | 现货 |
产品描述 | Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. |
靶点活性 | COX-2:1.1 μM COX-1 |
体内活性 | The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon[2]. |
细胞实验 | Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference) |
别名 | Arcoxia, MK-663, Tauxib, L-791456, Nucoxia, Desvenlafaxine, 依托考昔 |
分子量 | 358.84 |
分子式 | C18H15ClN2O2S |
CAS No. | 202409-33-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 43 mg/mL (119.8 mM)
DMSO: 66 mg/mL (183.9 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.7868 mL | 13.9338 mL | 27.8676 mL | 69.6689 mL |
5 mM | 0.5574 mL | 2.7868 mL | 5.5735 mL | 13.9338 mL | |
10 mM | 0.2787 mL | 1.3934 mL | 2.7868 mL | 6.9669 mL | |
20 mM | 0.1393 mL | 0.6967 mL | 1.3934 mL | 3.4834 mL | |
50 mM | 0.0557 mL | 0.2787 mL | 0.5574 mL | 1.3934 mL | |
100 mM | 0.0279 mL | 0.1393 mL | 0.2787 mL | 0.6967 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Etoricoxib 202409-33-4 Immunology/Inflammation Neuroscience COX MK-0663 L 791456 MK 0663 Arcoxia Inhibitor MK663 MK-663 Tauxib L-791456 inhibit MK0663 MK 663 Nucoxia Cyclooxygenase L791456 Desvenlafaxine 依托考昔 inhibitor